Swedish Orphan Biovitrum ABSWOBY 67 PEG Ratio is 2.49 as of Jun. 25, 2026, which is 83% above its 10-year median of 1.36. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.20 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 348 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 65.23% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's PEG Ratio or its related term are showing as below:
SWOBY'
s PEG Ratio Range Over the Past 10 Years
Min: 0.18 Med: 1.36 Max: 10.53
Current: 2.49
During the past 13 years, Swedish Orphan Biovitrum AB's highest PEG Ratio was 10.53. The lowest was 0.18. And the median was 1.36.
SWOBY's PEG Ratio is ranked worse than 65.23% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.72
vs SWOBY: 2.49
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Swedish Orphan Biovitrum AB PEG Ratio Related Terms
Swedish Orphan Biovitrum AB PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Swedish Orphan Biovitrum AB (SWOBY) has a PEG Ratio of 2.49 as of Jun. 25, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 83% above median its historical median of 1.36. Over the past decade, Swedish Orphan Biovitrum AB's PEG Ratio has ranged from 0.18 to 10.53. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #227 out of 348 companies in the Drug Manufacturers industry, placing it in the top 65.2%.
Is Swedish Orphan Biovitrum AB's PEG Ratio too high?
Swedish Orphan Biovitrum AB's current PEG Ratio of 2.49 is 83% above median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 10.53. The Drug Manufacturers industry median PEG Ratio is 1.72. Swedish Orphan Biovitrum AB's value of 2.49 is 44.8% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #227 out of 348 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #227 out of 348 companies for PEG Ratio. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median PEG Ratio is 1.72. Swedish Orphan Biovitrum AB's value of 2.49 is 44.8% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own PEG Ratio has ranged from 0.18 to 10.53 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 1.72, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current PEG Ratio of 2.49 is 44.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current PEG Ratio is 2.49, which is 83% above median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.20, compared to a current price of $23.18 — trading 34.8% above its estimated fair value. The current PEG Ratio is 2.49, which is 83% above median its 10-year median of 1.36 and 44.8% above the Drug Manufacturers industry median of 1.72. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current PEG Ratio is 2.49 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 34.8% above its estimated GF Value™ of $17.20.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
PEG Ratio: 2.49 (83% above median its 10-year median of 1.36)
GF Value™: $17.20 vs. price of $23.18 (34.8% above fair value)
Industry Position: 44.8% above the Drug Manufacturers median (#227 of 348)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
